Saudi Arabia

Eastern Mediterranean Region

I. Epidemiological profile

Population (UN)	2015	%
Number of active foci	31	
Number of people living within active foci	43,000	0
Malaria-free (0 cases)	31,500,000	100
Total	31,543,000	

Parasites and vectors

Plasmodium species:	*P. falciparum (100%), P.vivax (0%)*
Major anopheles species:	*An. arabiensis, An. sergentii, An. stephensi, An. fluviatilis, An. multicolor*

Reported confirmed cases (health facility):	83	Estimated cases:	<100
Confirmed cases at community level:	-		
Reported deaths:	0	Estimated deaths:	0

II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted
ITN	ITNs/ LLINs distributed free of charge	Yes	1980
	ITNs/ LLINs distributed to all age groups	Yes	1980
IRS	IRS is recommended	Yes	1963
	DDT is authorized for IRS	No	-
Larval control	Use of larval control recommended	Yes	-
IPT	IPT used to prevent malaria during pregnancy	N/A	-
Diagnosis	Patients of all ages should receive diagnostic test	Yes	-
	Malaria diagnosis is free of charge in the public sector	Yes	1963
Treatment	ACT is free of charge for all ages in public sector	Yes	1963
	The sale of oral artemisinin-based monotherapies (oAMTs)	Never allowed	-
	Single dose of primaquine is used as gametocidal medicine for P. falciaprum	Yes	1985
	Primaquine is used for radical treatment of P. vivax	Yes	-
	G6PD test is a requirement before treatment with primaquine	Yes	1985
	Directly observed treatment with primaquine is undertaken	No	-
	System for monitoring adverse reactions to antimalarials exists	No	1990
Surveillance	ACD for case investigation (reactive)	Yes	1980
	ACD of febrile cases at community level (pro-active)	Yes	1980
	Mass screening is undertaken	Yes	-
	Uncomplicated P. falciparum cases routinely admitted	No	-
	Uncomplicated P. vivax cases routinely admitted	No	-
	Foci and case investigation undertaken	Yes	1990
	Case reporting from private sector is mandatory	Yes	-

Antimalarial treatment policy	Medicine	Year adopted
First-line treatment of unconfirmed malaria	-	-
First-line treatment of P. falciparum	AS+SP+PQ	2012
Treatment failure of P. falciparum	AL	2007
Treatment of severe malaria	AS; AM; QN	2015
Treatment of P. vivax	CQ+PQ(14d)	-
Dosage of Primaquine for radical treatment of P. vivax		0.25 mg/Kg (14 days)
Type pf RDT used		P.f + P.v specific (Combo)

Therapeutic efficacy tests (clinical and parasitological failure, %)

Medicine	Year	Min	Median	Max	Follow-up	No of studies	Species

Insecticide susceptibility bioassays (reported resistance to at least one insecticide for any vector at any locality)

Year	Pyrethroid	DDT	Carbamate	Organophosphate	Species/complex tested
2010–2014	No				An. arabiensis

III. Financing

Sources of financing



Government expenditure by intervention in 2015 2015



IV. Coverage

Coverage of ITN and IRS



Cases tested



V. Impact

Cases treated



Test positivity



Confirmed malaria cases per 1000 and ABER



Number of malaria cases